An observational study in Depressive Disorder, Major, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-08.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Observational
The primary objective for this study is to assess the impact of a measurement based treatment program (MBT) on Major Depressive Disorder (MDD) remission rates in patients whose primary care provider (PCP) receives monthly patient-reported depression severity reports compared to patients whose PCP does not receive monthly reports.
2,805 studies on the registry are indexed under Depressive Disorder, Major; 565 are open to participants now.
This study's enrollment of 914 is above the median of 135 across 365 observational studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 293 studies on the registry; 18 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 70 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Primary care clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention sites will receive the results of the patient-reported depression severity collected during the phone interviews on a monthly basis. The patients in the intervention arm will be interviewed by phone once per month for 6 months.
The usual care sites will receive the results of the patient-reported depression severity at the end of the study. Patients in the usual care arm will be interviewed at 3 months and 6 months post study enrollment.
Remission rate assessed by the Patient Health Questionnaire - 9 item (PHQ-9) instrument
Time frame: Measured at baseline
Remission rate assessed by the Patient Health Questionnaire - 9 item (PHQ-9) instrument
Time frame: Follow-up upto 6 months
Response rate assessed by the PHQ-9 instrument
Time frame: 6 months
The medication prescribed including refills, dose titrations, switching and augmentation
Time frame: 6 months
Health care utilizations including office visits, emergency room visits and hospitalization
Time frame: 6 months
No study locations are listed for this record.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otsuka Pharmaceutical Development & Commercialization, Inc. →